Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
Adrenocortical Carcinoma, Brain and Central Nervous System Tumors, Head and Neck Cancer
About this trial
This is an interventional treatment trial for Adrenocortical Carcinoma focused on measuring childhood brain tumor, childhood infratentorial ependymoma, childhood supratentorial ependymoma, recurrent adult soft tissue sarcoma, recurrent childhood brain tumor, childhood liver cancer, stage IV childhood liver cancer, recurrent childhood liver cancer, advanced malignant mesothelioma, recurrent malignant mesothelioma, localized unresectable adult primary liver cancer, advanced adult primary liver cancer, recurrent adult primary liver cancer, recurrent adult brain tumor, stage IV adrenocortical carcinoma, recurrent adrenocortical carcinoma, stage IV papillary thyroid cancer, stage IV follicular thyroid cancer, thyroid gland medullary carcinoma, anaplastic thyroid cancer, recurrent thyroid cancer, adult brain stem glioma, adult medulloblastoma, adult glioblastoma, metastatic pheochromocytoma, recurrent pheochromocytoma, childhood soft tissue sarcoma, metastatic childhood soft tissue sarcoma, recurrent childhood soft tissue sarcoma, childhood high-grade cerebral astrocytoma, childhood oligodendroglioma, adult anaplastic astrocytoma, adult myxopapillary ependymoma, adult anaplastic ependymoma, adult anaplastic oligodendroglioma, adult mixed glioma, adult pilocytic astrocytoma, adult subependymoma, recurrent childhood brain stem glioma, recurrent childhood cerebellar astrocytoma, recurrent childhood cerebral astrocytoma, recurrent childhood medulloblastoma, recurrent childhood visual pathway and hypothalamic glioma, recurrent childhood ependymoma, stage IV adult soft tissue sarcoma, adult oligodendroglioma, adult giant cell glioblastoma, adult gliosarcoma, adult diffuse astrocytoma
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically proven soft tissue sarcoma, glioma, mesothelioma, hepatoma, thyroid cancer, or adrenal cancer with clinical, radiological, or histologic evidence of incurability Patients with thyroid cancer must have failed radioactive iodine Measurable or evaluable disease PATIENT CHARACTERISTICS: Age: 65 and under Performance status: ECOG 0-2 Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least 140,000/mm3 Hepatic: Bilirubin normal Renal: Creatinine less than 1.47 mg/dL Cardiovascular: Left ventricular ejection fraction at least 50% by MUGA scan No congestive heart failure No severe, uncontrolled hypertension No ischemia, life-threatening arrhythmia, or conduction disturbance by ECG Other: No allergy to study medications No uncontrolled infection No active abuse of ethanol that would preclude treatment No other prior or concurrent malignancy Not pregnant Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No more than 1 prior chemotherapy regimen No prior anthracycline or cisplatin At least 3 weeks since other prior chemotherapy and recovered Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics No prior radiotherapy to more than 25% of bone marrow At least 3 weeks since other prior radiotherapy and recovered Surgery: Not specified
Sites / Locations
- Ottawa Regional Cancer Centre at Ottawa Hospital - General Campus